PriceTargets.com logo

Calidi Biotherapeutics - CLDI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.25
  • Forecasted Upside: 1,549.75%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.20 As of 05/3/2024 09:52 PM ET
▼ -0.004 (-1.99%)

This chart shows the closing price for CLDI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Calidi Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLDI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLDI

Analyst Price Target is $3.25
▲ +1,549.75% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Calidi Biotherapeutics in the last 3 months. The average price target is $3.25, with a high forecast of $4.50 and a low forecast of $2.00. The average price target represents a 1,549.75% upside from the last price of $0.20.

This chart shows the closing price for CLDI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Calidi Biotherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/6/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/21/2024Robert W. BairdLower TargetOutperform ➝ Outperform$9.00 ➝ $4.50
3/21/2024HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $2.00
11/22/2023HC WainwrightInitiated CoverageBuy$11.00
10/9/2023Robert W. BairdInitiated CoverageOutperform$9.00
(Data available from 5/4/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/7/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/6/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/6/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/5/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/4/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2024

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Calidi Biotherapeutics logo
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.20
Low: $0.18
High: $0.21

50 Day Range

MA: N/A

52 Week Range

Now: $0.20
Low: $0.14
High: $13.79

Volume

503,900 shs

Average Volume

2,439,383 shs

Market Capitalization

$7.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Calidi Biotherapeutics?

The following Wall Street analysts have issued stock ratings on Calidi Biotherapeutics in the last twelve months: HC Wainwright, and Robert W. Baird.
View the latest analyst ratings for CLDI.

What is the current price target for Calidi Biotherapeutics?

2 Wall Street analysts have set twelve-month price targets for Calidi Biotherapeutics in the last year. Their average twelve-month price target is $3.25, suggesting a possible upside of 1,549.7%. Robert W. Baird has the highest price target set, predicting CLDI will reach $4.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for Calidi Biotherapeutics in the next year.
View the latest price targets for CLDI.

What is the current consensus analyst rating for Calidi Biotherapeutics?

Calidi Biotherapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLDI will outperform the market and that investors should add to their positions of Calidi Biotherapeutics.
View the latest ratings for CLDI.

What other companies compete with Calidi Biotherapeutics?

Other companies that are similar to Calidi Biotherapeutics include Creative Medical Technology, Fresh Tracks Therapeutics, Palisade Bio, Titan Pharmaceuticals and LadRx. Learn More about companies similar to Calidi Biotherapeutics.

How do I contact Calidi Biotherapeutics' investor relations team?

Calidi Biotherapeutics' physical mailing address is 4475 Executive Drive, Suite 200, San Diego, CA 92121, United States. The company's listed phone number is 858-794-9600 and its investor relations email address is [email protected]. The official website for Calidi Biotherapeutics is calidibio.com. Learn More about contacing Calidi Biotherapeutics investor relations.